GeneDx is trading at $92.96, down -4.98%, with no credible same-day company-specific catalyst identified.

  • GeneDx declined despite broader markets trading higher on September 22, 2026.
  • Recent coverage concerns the September 9 NPC GenomeComplete program, rather than a new announcement.
  • A September 18 report noted the CEO’s $1.03 million stock sale, but available coverage does not explicitly link it to the decline.